Taysha Gene Therapies (TSHA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TSHA Taysha Gene Therapies

Watchlist

2.3000
+0.0300+1.32%

Close Jul 26 16:00 ET

2.3000
0.00000.00%

Post 18:18 ET

463.17MMarket Cap-2948P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsJul 26 07:31 ET · Ratings
Buy Rating Affirmed: Taysha Gene Therapies' TSHA-102 Shows Promising Efficacy and Quality of Life Improvements in Rett Syndrome
TipRanksJul 26 06:36 ET · Ratings
Express News | Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
BenzingaJul 23 05:35 ET
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
ReutersJul 5 08:00 ET
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene TherapiesJul 5 00:00 ET
Board Observer of Taysha Gene Therapies Picks Up 5.7% More Stock
Simply Wall StJul 4 07:43 ET

Comments

Jaguar8

Jun 25 17:35

NEWS

$Taysha Gene Therapies(TSHA.US)$
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (Nasdaq: TSHA) has announced a public offering of up to $75 million in common stock and pre-funded warrants. This offering allows certain investors the option to purchase pre-funded warrants instead of common stock. Additionally, underwriters Jefferies, Goldman Sachs, and Cantor have a 30-day option to buy up to 15% more shares under the same...

HotShot369

Jun 18 11:38

Follow the motion and don't get lost in the ocean :D

$Taysha Gene Therapies(TSHA.US)$

Trytosaveabit

Jun 18 08:48

Hehehe

$Taysha Gene Therapies(TSHA.US)$ Nothing but good/encouraging data and its gets slammed!

Trytosaveabit

Jun 18 06:35

Update

$Taysha Gene Therapies(TSHA.US)$ Taysha Gene Therapies: Tsha-102 Well-Tolerated in Both Adult Patients Treated, With No Serious Adverse Events or Dose-Limiting Toxicities

Trytosaveabit

Jun 12 06:05

Watching for data outa this!

$Taysha Gene Therapies(TSHA.US)$ Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time
Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrf...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

TSHA Taysha Gene Therapies

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target